Accessibility Menu
MediciNova Stock Quote

MediciNova (NASDAQ: MNOV)

$1.21
(-0.8%)
-0.01
Price as of October 23, 2025, 10:57 a.m. ET

KEY DATA POINTS

Current Price
$1.21
Daily Change
(-0.8%) $0.01
Day's Range
$1.2 - $1.22
Previous Close
$1.22
Open
$1.21
Beta
0.73
Volume
19,861
Average Volume
44,903
Market Cap
59.8M
Market Cap / Employee
$1.22M
52wk Range
$1.13 - $2.55
Revenue
-
Gross Margin
-0.02%
Dividend Yield
N/A
EPS
-$0.24
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

MediciNova Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
MNOV-32.6%-77.57%-25.84%-89%
S&P+14.5%+93.32%+14.09%+376%

MediciNova Company Info

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.13M0.0%
Gross Profit$0.01M345.5%
Gross Margin9.80%0.0%
Market Cap$64.25M-9.0%
Market Cap / Employee$4.94M0.0%
Employees130.0%
Net Income-$3.28M-24.8%
EBITDA-$3.60M-18.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$34.26M-22.7%
Accounts Receivable$0.13M0.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.12M-61.3%
Short Term Debt$0.18M-2.7%

Ratios

Q2 2025YOY Change
Return On Assets-21.43%-8.8%
Return On Invested Capital-17.19%-0.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$2.31M18.0%
Operating Free Cash Flow-$2.31M17.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.791.871.361.299.01%
Price to Sales73.5771.1270.63477.35-
Price to Tangible Book Value2.402.531.881.8116.32%
Enterprise Value to EBITDA-18.52-19.83-11.07-8.41-4.50%
Return on Equity-17.2%-19.2%-20.3%-22.7%70.09%
Total Debt$0.46M$0.41M$0.36M$0.30M-38.71%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.